Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-Risk Neuroblastoma: A Groupwide Historically Controlled Phase III Study
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Age: Between 0 - 1 Years
Gender: Male or Female
12 months of age at diagnosis with INRG stage L1 or stage M neuroblastoma or nrollment on ANBLOOB1 is required for all newly diagnosed patients
Must have newly diagnosed v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN) non-amplified neuroblastoma or MYCN non-amplified ganglioneuroblastoma verified by histology
Patients with MYCN amplified tumors
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required